Inhibition of adenylate cyclase attenuates adenosine receptor-mediated relaxation in coronary artery.
This study was designed to evaluate whether the adenylate cyclase inhibitor 2',5'-dideoxyadenosine (DDA) would attenuate the relaxation produced by adenosine analogs in order to provide functional evidence in support of the working hypothesis that adenosine receptor-mediated relaxation of coronary artery involves adenylate cyclase. Rings from porcine left anterior descending coronary artery were mounted in organ chambers for measurement of isometric force. Rings contracted with KCl (30 mM) relaxed in a concentration-dependent manner to 2-chloroadenosine (CAD), 5'-N-ethylcarboxamidoadenosine (NECA), isoproterenol, sodium nitroprusside (SNP) and forskolin. Treatment of coronary rings with DDA (50 microM) significantly attenuated the relaxation produced by CAD, NECA, forskolin and isoproterenol, but had no effect on the relaxation response to SNP. The nucleoside transport inhibitor dilazep (10 microM) completely reversed the inhibitory effect of DDA on the relaxation produced by forskolin and CAD, whereas dilazep only partially reversed the DDA inhibition of NECA-induced relaxation. In a membrane preparation from porcine coronary artery CAD, but not NECA, increased cyclic AMP production in a GTP-dependent manner. DDA significantly decreased basal cyclic AMP production and also decreased CAD-, forskolin-, GTP- and NaF-stimulated cyclic AMP production. These results provide functional and biochemical evidence in support of the working hypothesis that adenosine receptor-mediated coronary relaxation involves adenylate cyclase. Furthermore, the results from this study suggest that the signaling mechanisms responsible for adenosine receptor-mediated coronary relaxation are more complicated than a single receptor coupled with adenylate cyclase because 1) dilazep completely reversed the inhibitory effect of DDA on the CAD relaxation but not the NECA relaxation, and 2) NECA did not increase cyclic AMP production.
Sabouni
M H
MH
Department of Pharmacology, School of Medicine, East Carolina University, Greenville, North Carolina.
Cushing
D J
DJ
Makujina
S R
SR
Mustafa
S J
SJ
D015762:2-Chloroadenosine / Q000494:pharmacology; D000241:Adenosine / Q000031:analogs & derivatives / Q000494:pharmacology; D019830:Adenosine-5'-(N-ethylcarboxamide); D000067956:Adenylyl Cyclase Inhibitors; D000818:Animals; D005576:Colforsin / Q000494:pharmacology; D003331:Coronary Vessels / Q000187:drug effects* / Q000201:enzymology; D000242:Cyclic AMP / Q000096:biosynthesis; D016048:Dideoxyadenosine / Q000031:analogs & derivatives / Q000494:pharmacology; D004109:Dilazep / Q000494:pharmacology; D006160:Guanosine Triphosphate / Q000494:pharmacology; D066298:In Vitro Techniques; D009126:Muscle Relaxation / Q000187:drug effects* / Q000502:physiology; D011983:Receptors, Purinergic / Q000502:physiology*; D012969:Sodium Fluoride / Q000494:pharmacology; D013552:Swine; D014665:Vasodilator Agents / Q000494:pharmacology
D000067956:Adenylyl Cyclase Inhibitors; D011983:Receptors, Purinergic; D014665:Vasodilator Agents; D015762:2-Chloroadenosine; D005576:Colforsin; D019830:Adenosine-5'-(N-ethylcarboxamide); D016048:Dideoxyadenosine; D006160:Guanosine Triphosphate; D012969:Sodium Fluoride; C021008:2',5'-dideoxyadenosine; D000242:Cyclic AMP; D004109:Dilazep; D000241:Adenosine